1,728 件 ・ 関連度順
概要と使いどころ
Provides guidance for performing causal interventions on PyTorch models using pyvene's declarative intervention framework. Use when conducting causal tracing, activation patching, interchange intervention training, or testing causal hypotheses about model behavior.
日本語の概要は準備中です。原文の説明を表示しています。
Provides guidance for training and analyzing Sparse Autoencoders (SAEs) using SAELens to decompose neural network activations into interpretable features. Use when discovering interpretable features, analyzing superposition, or studying monosemantic representations in language models.
日本語の概要は準備中です。原文の説明を表示しています。
Expert guidance for distributed training with DeepSpeed - ZeRO optimization stages, pipeline parallelism, FP16/BF16/FP8, 1-bit Adam, sparse attention
日本語の概要は準備中です。原文の説明を表示しています。
Expert guidance for fine-tuning LLMs with Axolotl - YAML configs, 100+ models, LoRA/QLoRA, DPO/KTO/ORPO/GRPO, multimodal support
日本語の概要は準備中です。原文の説明を表示しています。
Guided statistical analysis with test selection and reporting. Use when you need help choosing appropriate tests for your data, assumption checking, power analysis, and APA-formatted results. Best for academic research reporting, test selection guidance. For implementing specific models programmatically use statsmodels.
日本語の概要は準備中です。原文の説明を表示しています。
Optimize tool descriptions in ToolUniverse JSON configs for clarity and usability. Reviews descriptions for missing prerequisites, unexpanded abbreviations, unclear parameters, and missing usage guidance. Use when reviewing tool descriptions, improving API documentation, or when user asks to check if tools are easy to understand.
日本語の概要は準備中です。原文の説明を表示しています。
Guidance for distinctive, intentional visual design when building new UI or reshaping an existing one. Helps with aesthetic direction, typography, and making choices that don't read as templated defaults.
日本語の概要は準備中です。原文の説明を表示しています。
Write concise technical guidance, PR notes, architecture explanations, and reproducible verification reports.
日本語の概要は準備中です。原文の説明を表示しています。
Docker image reviews, optimization, and step-building guidance. Analyzes Dockerfiles for best practices, security issues, and anti-patterns.
日本語の概要は準備中です。原文の説明を表示しています。
Evaluates and implements age estimation and verification technologies for online services. Covers facial age estimation, digital ID verification, self-declaration with risk assessment, AI-based age estimation, and the accuracy versus privacy tradeoff. Includes ICO guidance and euCONSENT framework. Keywords: age verification, age estimation, facial analysis, digital ID, children, online safety.
日本語の概要は準備中です。原文の説明を表示しています。
Enhanced architecture guidance for voice-first Brazilian fintech applications. Use when designing voice interfaces, implementing PIX/Boletos, optimizing financial systems, or making technology stack decisions for Brazilian market applications. Integrates with docs/ content, MCP tools for Brazilian market research, enhanced validation scripts, and comprehensive Brazilian compliance patterns.
日本語の概要は準備中です。原文の説明を表示しています。
Help and guidance for Azure DevOps synchronization with SpecWeave increments. Use when asking how to set up ADO sync, configure credentials, or troubleshoot integration issues. For actual syncing, use /sw-ado:sync command.
日本語の概要は準備中です。原文の説明を表示しています。
You are an accessibility expert specializing in WCAG compliance, inclusive design, and assistive technology compatibility. Conduct audits, identify barriers, and provide remediation guidance.
日本語の概要は準備中です。原文の説明を表示しています。
Use when you need framework-agnostic OpenAPI 3.x guidance — spec structure, metadata and versioning, paths and operations, reusable schemas, security schemes, examples, documentation quality, contract validation (e.g. Spectral), breaking-change awareness, and handoffs to codegen — without choosing Spring Boot, Quarkus, or Micronaut. This should trigger for requests such as Review an OpenAPI; Improve an OpenAPI; Improve API contract; Improve API schema design. Part of cursor-rules-java project
日本語の概要は準備中です。原文の説明を表示しています。
SSL/БСП subsystems guidance and search via 1c-mcp_ssl_server MCP. Use when working with standard library subsystems - users, files, print forms, background jobs, email, common utilities.
日本語の概要は準備中です。原文の説明を表示しています。
Prepares statistical reports for clinical trials following CONSORT 2025, SPIRIT 2025, ICH E9(R1) estimands, and FDA 2023 covariate adjustment guidance. Covers Table 1 generation, analysis populations (ITT/FAS/PP/Safety), the 5 ICH E9(R1) intercurrent-event strategies, MMRM under MAR (mmrm), reference-based MI (rbmi J2R/CR/CIR), Permutt tipping-point sensitivity, and Rubin's-rules vs frequentist variance debate. Use when preparing regulatory submissions, defining estimands, or implementing missing-data sensitivity analyses.
日本語の概要は準備中です。原文の説明を表示しています。
Queries PharmGKB / CPIC / DPWG for drug-gene interactions; calls CYP2D6/CYP2C9/CYP2C19/DPYD/TPMT/NUDT15/UGT1A1/SLCO1B1 star alleles and phenotype with PharmCAT, Cyrius (CYP2D6 structural variants), Aldy, Stargazer; applies Caudle 2020 activity-score translation. Use when implementing pharmacogenomic-guided prescribing, applying CPIC vs DPWG guidance, screening HLA risk alleles for ICI / antiepileptics / abacavir, or interpreting compound TPMT+NUDT15 thiopurine risk.
日本語の概要は準備中です。原文の説明を表示しています。
Performs logistic regression for clinical trial outcomes (binary, ordinal, multinomial) with marginal-vs-conditional estimand reporting per FDA 2023 covariate adjustment guidance, g-computation/standardisation for marginal effects, modified Poisson for RR, Brant test for proportional odds, Firth penalty for separation, and Hauck-Donner detection. Use when modeling binary or ordinal endpoints in confirmatory or exploratory clinical trials.
日本語の概要は準備中です。原文の説明を表示しています。
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
日本語の概要は準備中です。原文の説明を表示しています。
Analyzes CUT&RUN (Skene Henikoff 2017) and CUT&Tag (Kaya-Okur 2019) chromatin profiling data. Handles SEACR vs MACS2 peak calling (with the btaf375 2025 benchmark guidance), pA-MNase vs pA-Tn5 vs pAG-Tn5 chimera differences, E. coli spike-in carryover normalization, IgG-only control logic (no input), characteristic fragment-size signatures (25-75 bp for CUT&Tag), and lower depth requirements (5M reads typical vs 25M for ChIP). Use when calling peaks from CUT&RUN/CUT&Tag, scaling by E. coli spike-in carryover, choosing SEACR norm mode, or comparing CUT&RUN/Tag results to traditional ChIP.
日本語の概要は準備中です。原文の説明を表示しています。
Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.
日本語の概要は準備中です。原文の説明を表示しています。
Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.
日本語の概要は準備中です。原文の説明を表示しています。
Computes and interprets treatment effect measures (OR, RR, RD, HR, NNT) with calibrated confidence intervals (Wilson, Newcombe, Miettinen-Nurminen, MOVER, profile likelihood, Bender NNT) and reports marginal vs conditional estimands per FDA 2023 covariate adjustment guidance. Use when reporting treatment effects in confirmatory trials, comparing effect sizes across studies, or constructing forest plots.
日本語の概要は準備中です。原文の説明を表示しています。
Trim multiple sequence alignments using ClipKIT, trimAl, BMGE, Divvier, or HMMcleaner with mode selection guidance per downstream goal. Use when removing unreliable columns or contaminating residues before phylogenetic inference, HMM building, or selection analysis.
日本語の概要は準備中です。原文の説明を表示しています。